Shares of Boston Scientific Corp. BSX slid 1.03% to $103.10 Tuesday, on what proved to be an all-around positive trading ...

Boston Scientific Corp. closed 2.80% short of its 52-week high of $107.17, which the company achieved on February 5th.

The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.

Boston Scientific leads in MedSurg and Cardiovascular with strong Q1 growth, solid margins, and smart acquisitions. Find out ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

With a market cap of $155.7 billion, Boston Scientific Corporation (BSX) is a global medical device company operating through ...

Boston Scientific ends global sales of ACURATE valves and halts FDA pursuit, citing rising regulatory burdens; expects to ...

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Boston Scientific said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other markets due to increased clinical and ...

Camille Chang Gilmore, Boston Scientific’s global chief DEI officer announced she is leaving the company after two decades of ...

Boston Scientific has a better P/E ratio of 76.28 than the aggregate P/E ratio of 53.33 of the Health Care Equipment & Supplies industry. Ideally, one might believe that Boston Scientific Inc. might ...